A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Trial Profile

A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs NBTXR 3 (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaEngine
  • Most Recent Events

    • 09 Nov 2017 According to a company media release, Nanobiotix filed a protocol amendment of this study to include 44 additional patients. Nanobiotix is also opening 12-15 additional sites in Europe to expand the development of this indication.
    • 09 Nov 2017 According to a Nanobiotix media release, Prof. Christophe Le Tourneau, the Principal Investigator of the trial, presented an update during the Trends in Head and Neck Oncology conference (THNO). Interim update on the expansion cohort is expected in mid-2018.
    • 31 Aug 2017 According to a Nanobiotix media release, results from this trial were presented at the American Society of Clinical Oncology (ASCO) in June 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top